← All indications
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.
Subtype terms (7)
More specific conditions that are subtypes of Streptococcal Infections in the MeSH hierarchy.
- Ecthyma
2 drugs approved
- Endocarditis, Subacute Bacterial
- Erysipelas
5 drugs (4 approved, 1 experimental)
- Impetigo
15 drugs (10 approved, 5 experimental)
- Pneumococcal Infections
68 drugs (36 approved, 32 experimental)
- Rheumatic Fever
16 drugs (8 approved, 8 experimental)
- Scarlet Fever
2 drugs approved
Drugs by status
Approved for this indication (2)
Phase 4 trials (12)
- procaine benzylpenicillin
- benzydamine
- ibuprofen
- albumin (Human)
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- acetaminophen
- immune globulin (human)
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- pneumococcal 7-valent conjugate vaccine
- cefuroxime
- haemophilus influenzae type b conjugate vaccine
- Inactivated polio virus - Enhanced
Phase 3 trials (16)
- 23-valent pneumococcal polysaccharide vaccine
- diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- tritanrix-hepb
- hepatitis a vaccine, inactivated
- multi-valent pneumococcal conjugate vaccine
- attenuated measles vaccine - Edmonston strain
- live oral poliovirus type 1, 2 and 3
- 10-valent Pneumococcal Conjugate Vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- polio, inactivated poliovirus vaccine
- technetium tc-99m pentetate kit
- human rotavirus, live attenuated
- gbs-nn/nn2
- meningococcal (groups A, C, Y, W) diphtheria toxoid conjugate vaccine
Phase 2 trials (19)
- linezolid
- haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
- gsk2830929a
- gsk2830930a
- gsk 2189242a
- rabies vaccine (purified chick embryo cell vaccine)
- radezolid
- oritavancin
- alprostadil
- yellow fever vaccine 17d strain
- gbs vaccine
- group b streptococcus trivalent vaccine
- multivalent group b streptococcus vaccine
- hexavalent pneumococcal polysaccharide vaccine
- group b streptoccous 6-valent polysaccharide conjugate vaccine
- j8-k4s2
- p*17-k4s2
- Hexavalent anti capsular polysaccharide
- gbs-06
Phase 1 trials (12)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (24)
- Targanta
- Pfizer
- Novartis
- Minervax ApS
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Case Western Reserve University
- University of London
- Duke University
- Stanford University
- Tufts University
- University of Iowa
- University of New Mexico
- Wayne State University
- University of Utah
- Melinta Therapeutics
- Regional Hospital Heilig Hart, Tienen, Belgium
- Medical Research Council, The Gambia
- University of Alabama, Birmingham
- Department of State for Health and Social Welfare, The Gambia
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- National Institute of Child Health and Human Development (NICHD)
- PATH
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (17)
- Basilea Pharmaceutica
- Telethon Kids Institute
- University of Melbourne
- University of Tennessee
- University of Auckland
- Nucleus Network Ltd
- University of Queensland
- Government of China
- Free University of Brussels
- National Health and Medical Research Council, Australia
- University of Wollongong
- The Peter Doherty Institute
- Griffith University
- Tianjin Cansino Biotechnology Inc
- Murdoch University
- Johnson and Johnson
- Simbec-Orion
Organization Involved with Other Experimental Indications (11)